Loading insider details...
Beta
Latest Form 4 (Sep 3, 2026): Sale of 2,768 DNLI shares, $64.9K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Denali Therapeutics Inc. (DNLI) | Sale | 2,768 | $64.9K |
| Aug 13, 2026 | Denali Therapeutics Inc. (DNLI) | Sale | 2,857 | $71.6K |
| Jan 8, 2026 | Denali Therapeutics Inc. (DNLI) | Sale | 17,218 | $284.1K |
| Jan 5, 2026 | Denali Therapeutics Inc. (DNLI) | Grant/Award | 57,700 | n/a |
| Aug 14, 2025 | Denali Therapeutics Inc. (DNLI) | Sale | 2,937 | $39.9K |
| Jan 8, 2025 | Denali Therapeutics Inc. (DNLI) | Sale | 12,255 | $247.8K |
| Jan 7, 2025 | Denali Therapeutics Inc. (DNLI) | Grant/Award | 54,180 | n/a |
| Dec 31, 2024 | Denali Therapeutics Inc. (DNLI) | Exercise/Conversion | 6,708 | $35.4K |
| Nov 26, 2024 | Denali Therapeutics Inc. (DNLI) | Exercise/Conversion | 20,516 | $14.0K |
| Nov 12, 2024 | Denali Therapeutics Inc. (DNLI) | Exercise/Conversion | 15,558 | $82.1K |